Regular and extended-release formulations of zolpidem [Ambien and Ambien CR; sanofi-aventis] have been granted paediatric exclusivity by the US FDA.

Source: Inpharma, Volume 1, Number 1567, 2006-12-09 , pp. 22-22(1)

Keywords: Children; Controlled-release-drugs; Development-status; Insomnia, treatment; Product-approvals; Zolpidem, therapeutic use

Document Type: Short communication

Links for this article

http://www.ingentaconnect.com/adis/inp/2006/00000001/00001567/art00063
http://openurl.ingenta.com/content?genre=article&issn=1173-8324&volume=1&issue=1567&spage=22&epage=22